Comparison of pregabalin with pramipexole for restless legs syndrome

New England Journal of Medicine

Volumn 370, Issue 7, 2014, Pages 621-631

  Allen, Richard P ^a   Chen, Crystal ^b   Garcia Borreguero, Diego ^c   Polo, Olli ^d   DuBrava, Sarah ^b   Miceli, Jeffrey ^b   Knapp, Lloyd ^b   Winkelman, John W ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c SLEEP RESEARCH INSTITUTE   (Spain)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAMIPEXOLE; PREGABALIN;

ADULT; AGED; ARTICLE; BACKACHE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INFLUENZA; INTERNATIONAL RESTLESS LEGS SYNDROME STUDY GROUP RATING SCALE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SCORING SYSTEM; SOMNOLENCE; SUICIDAL IDEATION; VOMITING; WEIGHT GAIN;

EID: 84893779614     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1303646     Document Type: Article

References (37)

1. Earley CJ, Silber MH. Restless legs syndrome: understanding its consequences and the need for better treatment. Sleep Med 2010;11:807-15.
2. Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: prevalence and characteristics. Sleep Med 2010;11:31-7.
3. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-92. (Pubitemid 40989594)
4. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982;39:739. (Pubitemid 12003440)
5. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52:938-43. (Pubitemid 29161600)
6. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 2006;21:1627-35. (Pubitemid 44742190)
7. Earley CJ. Restless legs syndrome. N Engl J Med 2003;348:2103-9. (Pubitemid 36583306)
8. Montplaisir J, Lorrain D, Godbout R. Restless legs syndrome and periodic leg movements in sleep: the primary role of dopaminergic mechanism. Eur Neurol 1991;31:41-3.
9. Allen RP, Ondo WG, Ball E, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med 2011;12:431-9.
10. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-13. (Pubitemid 26138225)
11. Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003;26:819-21. (Pubitemid 39610626)
12. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5:9-14. (Pubitemid 38145706)
13. Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 2011;12:440-4.
14. García-Borreguero D, Högl B, Ferini-Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord 2012;27:277-83.
15. Högl B, Garcia-Borreguero D, Trenkwalder C, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med 2011;12:351-60.
16. Walters AS, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology 1996;46:92-5. (Pubitemid 26156108)
17. Garcia-Borreguero D, Allen R, Kohnen R, et al. Loss of response during long-term treatment of restless legs syndrome: guidelines approved by the International Restless Legs Syndrome Study Group for use in clinical trials. Sleep Med 2010;11:956-7.
18. Boehringer Ingelheim. Mirapex prescribing information (http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing%20Information/PIs/Mirapex/Mirapex.pdf) .
19. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73:137-50. (Pubitemid 46329329)
20. Pfizer. Lyrica prescribing information (http://www.pfizer.com/files/ products/uspi-lyrica.pdf).
21. Allen R, Chen C, Soaita A, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 2010;11:512-9.
22. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19. (Pubitemid 36527231)
23. Allen RP, Burchell BJ, MacDonald B, Hening WA, Earley CJ. Validation of the self-completed Cambridge-Hopkins questionnaire (CH-RLSq) for ascertainment of restless legs syndrome (RLS) in a population survey. Sleep Med 2009;10:1097-100.
24. Hening WA, Allen RP, Washburn M, Lesage S, Earley CJ. Validation of the Hopkins telephone diagnostic interview for restless legs syndrome. Sleep Med 2008;9:283-9. (Pubitemid 351391728)
25. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-32. (Pubitemid 36527232)
26. Allen RP. Minimal clinically significant change for the International Restless Legs Syndrome Study Group rating scale in clinical trials is a score of 3. Sleep Med 2013;14:1229.
27. Quilici S, Abrams KR, Nicolas A, et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 2008;9:715-26.
28. García-Borreguero D, Kohnen R, Högl B, et al. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 2007;8: 455-63. (Pubitemid 46972002)
29. Högl B, Gschliesser V. RLS assessment and sleep questionnaires in practice - lessons learned from Parkinson's disease. Sleep Med 2007;8:Suppl 2:S7-S12. (Pubitemid 47040663)
30. Guy W. CGI, Clinical Global Impressions. In: ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976: 217-22.
31. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21. (Pubitemid 351147828)
32. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004; 26:925-35. (Pubitemid 38943041)
33. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, eds. Measuring functioning and well-being: the medical outcomes study approach. Durham, NC: Duke University Press, 1992:235-59.
34. Högl B, García-Borreguero D, Kohnen R, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 2010;257:230-7.
35. Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, doubleblind, placebo-controlled trial in the United States. Mov Disord 2010;25:1675-83.
36. Oertel W, Trenkwalder C, Beneš H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011;10:710-20.
37. Micheva KD, Taylor CP, Smith SJ. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol 2006;70:467-76. (Pubitemid 44092307)